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INTRODUCTION 
Arthritis is a form of joint disorder that involves 
chronic inflammation of one or more joints
1
. There are 
over 100 different forms of arthritis. The commonest 
form is osteoarthritis, which is the result of trauma to 
the joint, infection of the joint, or age. Other arthritis 
forms are rheumatoid arthritis, septic arthritis, psoriatic 
arthritis, and related autoimmune diseases. Rheumatoid 
arthritis (RA) is a potentially destructive disease with 
profound impact on joint pain and may be localized to 
the affected joint. The pain associated with arthritis is 
due to inflammation that occurs around the joint, 
damage to the joint from disease, daily wear and tear of 
joint, muscle strains caused by forceful movements 
against stiff painful joints and fatigue. Arthritis in 
children is common, and a major cause of potential 
morbidity with significant long-term consequences, 
joint damage and disability if left untreated
2
. 
RA is the most common cause of disability in the USA. 
More than 20 million individuals with arthritis have 
severe limitations in function on a daily basis
3
. Each 
year, arthritis results in nearly 1 million hospitalizations 
and close to 45 million outpatient visits to health 
care centres.  
Arthritis can make it very difficult for an individual to 
remain physically active, contributing to an increased 
risk of obesity, high cholesterol or vulnerability to heart 
disease. Individuals with arthritis are also at increased 
risk of depression, which may be related to fear of 
worsening symptoms. Therapy is aimed at relieving 
pain, maintaining or improving mobility and 
minimizing disability. It may induce medication, 
physical therapy, and patient education
3
. 
ANTI-INFLAMMATORY DRUGS USED FOR 
PAIN MANGEMENT IN ARTHIRITIS 
Patients with rheumatic diseases, including RA and 
osteoarthritis, almost universally describe pain and 
stiffness as important contributors to reduced health-
related quality of life. The treatment options available, 
non-steroidal anti-inflammatory drugs (NSAIDs) are the 
most widely used agents for symptomatic treatment
4
. 
Most frequently used NSAIDs in arthritic pain 
management are enlisted below: 
 Aspirin, Celecoxib, Diclofenac, Indomethacin 
 Diflunisal, Fenoprofen, Flurbiprofen, Ibuprofen, 
Ketoprofen, Naproxen 
 Ketorolac,  Meloxicam, Nabumetone, Oxaprozin, 
Piroxicam  
 Salsalate, Sulindac, Tolmetin etc. 
 
*For Correspondence 
Dr. Ashish Baldi 
Professor and Principal,  
I.S.F. College of Pharmacy,  
G.T. Road, N.H. 95, Moga,  
Punjab, India- 142001. 
Tel: +91-8968423848;  
E-mail: baldiashish@gmail.com 
ABSTRACT 
Rheumatoid arthritis is an auto-immune joint disorder involving pain and inflammation. Various approaches are used for pain 
management and relief from arthritis with single and multiple dose therapy. In single dose therapy, use of non-steroidal anti-
inflammatory drugs like diclofenac aceclofenac, celicoxib etc. reported many side effects mainly leading to decrease in 
production of prostaglandin and holding the ulcer. High dosing frequency of these drugs is also a major factor of risk. Recently 
developed novel formulations are especially suitable for achieving controlled and delayed release profile with low risk of dose 
dumping. These systems have received great attention of pharmaceutical industry as they deliver accurate amount of drug at the 
right time and location thus increasing patient compliance and economic feasibility and avoiding drug associated side effects. 
Present review mainly deals with the problem of ulceration in pain management, various approaches to overcome this and 
specifically explore the possibilities to apply novel drug delivery systems for this purpose. 
Keywords: Arthritis, Drug delivery systems, Gastroretentive, NSAIDs, Pain, Rheumatoid arthritis, Rheumatic pain 
management. 
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Role of NSAIDs in arthritic pain management 
NSAIDs are used as effective therapy for pain 
management to relieve pain, swelling (inflammation), 
and joint stiffness caused by arthritis. These drugs may 
also be used to treat other painful conditions such as 
dental pain, muscle aches, pain after surgery or 
parturition, but are not appropriate for long-term disease 
control
5
. The safety of NSAIDs has been closely 
monitored by regulatory authorities across the globe. 
These are used for the treatment of mild to moderate 
pain, fever and inflammation. NSAIDs mainly work by 
blocking the effect of chemicals called cyclo-oxygenase 
(COX) enzymes thereby decreasing prostaglandins 
synthesis. Some prostaglandins are produced at sites of 
injury or damage, and cause pain and inflammation. By 
blocking the effect of COX enzymes, fewer 
prostaglandins are produced, leading to pain and 
inflammation cessation
6
. 
Topical form of NSAIDs produces a higher local 
concentration of the drug, and target the inflammation 
site and pain, where it preferentially distributes. 
Achieving sufficiently high concentration to exert local 
therapeutic activity, for the effective distribution, skin 
absorption is most critical factor of the drug to the site 
of inflammation and thus it can affect the efficacy of 
topical formulation
7
. 
PROBLEMS ASSOCIATED WITH USE OF 
NSAIDs IN ARTHRITIS 
Symptomatic relief but not cure 
The most obvious symptoms indicating arthritic state 
and its severity are inflammation and pain in and around 
the affected joint. Anti-inflammatory drugs used for 
pain management in arthritic individuals provide 
relieves from pain for a certain time and reduce 
inflammation but no existing treatment modality 
ensures cure of arthritis. Hence, all NSAIDs offers only 
symptomatic relieve in RA
5
.  
High dose frequencies 
The recommended dose of NSAIDs for treating RA is 
generally given 3-4 times daily for e.g. diclofenac is 
given daily thrice at a dose of 50 mg. Rheumatoid 
arthritic treatment modulates the involvement of long 
term use of anti-inflammatory drugs for years. 
Furthermore due to increase in pain with severity of 
disease and age, patient start more frequent self 
medication of higher dosages. Furthermore 
simultaneous application of different dosages forms like 
tablets, gels, etc. also results in higher concentrations of 
drug in the body. Due to these reasons, NSAIDs 
induced toxicities and related complications arise in 
many patients. Frequent administration of these drugs at 
higher dose also results in decreased therapeutic 
effectiveness. Both toxicities and lack of efficacy result 
in high withdrawal rate, which question impact of these 
drugs on the underlining disease mechanistically. 
Conventional NSAIDs based treatment therapies have 
much well recognised toxicity and is incompletely 
effective with few patients. Diclofenac sodium, the 
most preferred NSAID in arthritic pain management is a 
non-steroidal, non-pyrazole compound with anti-
inflammatory, antipyretic and analgesic activity in 
laboratory animals. It has been shown to be well 
tolerated and effective in short term therapy of 
degenerative joint disorders and RA. In long term, 
frequent dosing show side effect in the patient
8
. 
NSAIDs associated side effect 
NSAIDs are reasonably safe medications, when low 
doses are taken for brief period. Side effects most 
commonly occur with large doses over a prolonged time 
(months or years). Some side effects are mild and go 
away on their own or after reducing the dose. Others 
may be more serious and need medical attention
9
. 
Common side effects of NSAIDs include: 
 GI gastropathy, abdominal cramps, stomach pain, 
stomach ulcers and heartburn. 
 Headaches, ringing in the ears and dizziness. 
 Allergic reactions such as rashes, wheezing, and 
throat swelling and 
 Liver or kidney problems, high blood pressure and 
increased bleeding tendency (especially with 
aspirin).  
Many of the adverse effects of NSAIDs are also related 
to inhibition of prostaglandin production, making their 
use problematic in some patient populations. The 
biology of prostaglandin as it relates to gastrointestinal, 
renal, and cardiovascular physiology and the 
pharmacologic properties of specific NSAIDs is a key 
to using these drugs safely
5
. 
NSAIDs induced ulceration: A cause of worry in 
arthritis 
Being acidic in nature, most of the NSAIDs (diclofenac, 
ibuprofen) are known to damage stomach lining and 
may also cause ulceration and perforation in extreme 
cases
10
. The lifetime risk of developing peptic ulcer is 
approximately 10%. However this situation becomes 
alarming in patients, who are receiving for long term in 
situations like RA for months and years. Development 
and peptic ulcers and associated pain is one of the major 
causes of withdrawal of NSAIDs and non compliance in 
rheumatic pain management. NSAIDs damage 
gastrointestinal mucosa by causing both local injuries 
and by systemically inhibiting prostaglandin 
production. However, current consensus on the 
pathogenesis of symptomatic peptic ulcer disease 
resulting from exposure to NSAID is mainly a 
consequence of systemic (post-absorptive) inhibition of 
GI mucosal COX activity rather than a local effect; 
NSAIDs are valuable agents in the treatment of arthritis 
and many other musculoskeletal disorders and as 
analgesics in a wide variety of clinical scenarios. 
However, as stated above, their use has been limited 
mainly by their association with mucosal injury to the 
upper gastrointestinal tract, including the development 
of peptic ulcer disease
11
. 
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APPROACHES TO OVERCOME NSAIDs 
INDUCED ULCERATION  
Combination with other drugs 
Antacid 
Antacids were usually co-prescribed with NSAIDs 
although no broad evidences were available as to the 
effects of antacids in preventing NSAID associated 
gastropathy
12
. A represent active survey of an outpatient 
prescription database was performed to measure the 
extent of such a combination and to explore its 
associated factors
13
. However, erratic absorption pattern 
of some NSAIDs upon co-administration with antacid 
should also be taken into consideration
14,15
. NSAID can 
also increase gastric acid secretion, although it is not 
clear whether such acts have any impact on ulcer 
formation or healing. Prostaglandins exert inhibitory 
acts on parietal cells, so the inhibition of their synthesis 
by NSAIDs can result in an increase in gastric acid 
secretion
16
. 
Cytoprotectant  
Cytoprotectant are said to enhance endogenous mucosal 
protection mechanism and provide a physical barrier 
over the surface of ulcer. These drugs are now day most 
frequently co-administrated with NSAIDs to prevent 
ulcer formation. Prostaglandin of E and I series have a 
generally protective action in the GI track and a 
deficiency in endogenous prostaglandin production may 
contribute to ulcer formation. 
Misoprostal, a synthetic prostaglandin E1 (PGE1) 
methyl ester analogue has potent anti-secretory and 
cytoprotective effects on the gastric and duodenal 
mucus
17
. Misoprostal is a stable prostaglandin analogue, 
has been shown in large studies to significantly reduce 
serious gastrointestinal side-effects due to the 
concurrent administration of NSAIDs and appears to be 
superior to ranitidine and sucralfate in preventing 
NSAID-induced gastric and dudenol ulcers. 
Misoprostal is absorbed rapidly when administered 
orally, vaginally, rectally or intracervically. The vaginal 
route is advantageous because peak levels are reached 
slowly and sustained for long time and this is associated 
with fewer side effects. It exerts a direct action on the 
parietal cell inhibiting the basal secretion of gastric acid 
as well as stimulation of production seen in response to 
food, histamine, pentagastrin and caffeine. It also 
increases mucosal blood flow and augments the 
secretion of mucus and bicarbonate
12
.     
Drug delivery approaches for prevention of NSAIDs 
induced ulceration 
Current status   
Presently most preferred treatment approaches for pain 
management in arthritis consists of diclofenac (NSAID) 
and misoprostol (a cytoprotectent) as mono- or 
combination therapy, with recommended dose of 50 mg 
and 200 µg respectively given 3-4 time daily. If this 
regiment is not tolerated, diclofenac may be given 50 
mg or 75 mg twice a day. Currently tablet and enteric 
coated tablet forms of diclofenac alone or in 
combination with misoprostol drug are available in 
market. Despite of several technological advancement 
in novel drug delivery system, only tablet and enteric 
coated tablets available in the market for oral 
administration of these drugs. By keeping in view above 
mentioned problems associated with use of NSAIDs in 
arthritic pain management, more specifically high 
frequency of dosing and ulceration, application of novel 
drug delivery systems may offer suitable, safe, 
therapeutically effective, more acceptable and cost 
efficient alternative. 
Controlled/sustained release formulations 
Sustained release systems include any system that 
achieves slow release of drug over an extended period 
of time or if the system is successful at maintaining 
constant drug levels in the target tissue or cells, it is 
considered a controlled-release system.  
The basic rationale behind sustained/controlled release 
drug delivery is altering the pharmacokinetics and 
pharmacodynamics of drugs by using customized novel 
drug delivery pattern and modification of molecular 
structure or physiological parameters inherent in a 
selected route of administration
18
. Thus, optimal design 
of a sustained/controlled release system necessitates a 
thorough understanding of the pharmacokinetics and 
pharmacodynamics of the drug. When the drug is 
administered in a conventional dosage form, it results in 
a fluctuation of drug concentration at the site of action 
(peak and valley pattern) and therefore in systemic 
circulation and tissue compartment. Improved 
efficiency in treatment, optimized therapy and more 
uniform blood concentration is the benefits of this drug 
administration method. Advantages of 
controlled/sustained release formulation include: 
 Reduction in fluctuation in drug level and hence 
more uniform pharmacological response with 
reduced frequent dosing and cure of control of 
condition more promptly with diminish the chances 
of ulcer induction.  
 Improved patient compliance. It has been found 
that there is an inverse relationship between the 
number of dosages per day and the compliance 
rate. 
 Although the initial unit cost of sustained release 
products is usually greater than that of conventional 
dosage forms because of the special nature of these 
products, the average cost of treatment over an 
extended time period may be less. Economy may 
also result from a decrease in nursing time and 
hospitalization time
19
.  
Gastroretentive/floating formulation 
Gastroretentive drug delivery is an approach to prolong 
gastric residence time. Over the last few decades, 
several gastroretentive drug delivery approaches being 
designed and developed, including high density 
(sinking) systems that is retained in the bottom of the 
stomach low density (floating) systems that causes 
buoyancy in gastric fluid
20
. Two type of floating 
system, single unit and multiple unit dosage form are 
available
21
 thereby targeting site-specific drug release in 
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the upper gastrointestinal tract (GIT) for local or 
systemic effects. Gastroretentive dosage forms can 
remain in the gastric region for long periods and hence 
significantly prolong the gastric retention time (GRT) of 
drugs
22
. The gastro retentive systems are advantageous 
for drugs absorbed through the stomach, e.g. ferrous 
salts, antacids
23
. 
Floating drug delivery system is also called the 
hydrodynamically balanced system (HBS)
24
. This type 
of drug delivery system is specifically beneficial to 
reduce NSAIDs induced peptic ulcers due to avoidance 
of direct contact of NSAIDs to stomach lining
25
, no 
dose dumping, decreased frequency of dosing, 
possibility of co-administration with 
antacids/cytoprotectent and better bioavailability
26
. The 
associated advantages with floating drug delivery 
systems are as follows: 
 Administration of floating dosage forms, tablet or 
capsules, will result in dissolution of the drug in the 
gastric fluid
27
. Drug dissolved in the gastric fluid 
would be available for absorption in the small 
intestine after emptying of the stomach contents. It 
is therefore expected that a drug will be fully 
absorbed from floating dosage forms if it remains 
in the solution form even at the alkaline pH of the 
intestine
28
.  
 Improves patient compliance by decreasing dosing 
frequency. 
 Bioavailability enhances despite first pass effect 
because fluctuations in plasma drug concentration 
are avoided; a desirable plasma drug concentration 
is maintained by continuous drug release
29
. 
 Better therapeutic effect of short half-life drugs can 
be achieved. 
 Superior to single unit dosage forms due to uniform 
drug release and no risk of dose dumping. 
 Avoidance of gastric irritation, because of 
sustained release effect, floatability and uniform 
release of drug through multi particulate system. 
Enteric coated drug delivery system 
Enteric refers to the small intestine; therefore enteric 
coating on the dosage form prevents the release of drug 
before it reaches the small intestine
30
. Most enteric 
coatings work by presenting a  surface that is stable to 
highly acidic pH of stomach, but breaks down rapidly at 
a less acidic (relatively more basic) pH. Enteric coating 
is suitable for drugs that have irritant effect in stomach 
(like NSAIDs) and drugs which are unstable in acidic 
pH of stomach. Thus, enteric coating is aimed to 
prevent the formulations from gastric fluid in the 
stomach and release the drug component in the 
intestinal region or once it has passed into the 
duodenum. The enteric coated tablet is the most 
common example of a delayed-action tablet product
31
. 
Advantages offered by enteric coated drug delivery 
system include: 
 Prevention from gastric distress or nausea due to 
irritation caused by certain drugs e.g. NSAIDs. 
 Protection of acid-labile drugs from the acidic pH 
of gastric fluid e.g. enzymes and certain antibiotics.  
 To deliver drugs that are optimally absorbed in the 
small intestine to their primary absorption site in 
their most concentrated form. 
 To deliver drugs intended for the local action in 
intestines. E.g. intestinal antiseptics could be 
delivered to their site of action in a concentrated 
form and bypass systemic absorption in the 
stomach.  
 To provide a delayed release component to repeat 
action tablets. 
Hence this strategy avoids contact of NSAIDs to 
mucosal lining of stomach result in prevention from 
associated irritation and erosion and may offer a 
suitable alternative to avoid NSAIDs induced 
ulceration
32
. 
Novel/Multiple unit dosage forms formulation 
(MUDF) 
Oral modified drug delivery systems can be classified in 
to two broad groups: single unit dosage forms (SUDFs) 
and multiple unit dosage forms (MUDFs). Several mini-
tablets can be either filled into hard capsules or 
compacted into bigger tablets that, after disintegration, 
release these subunits as multiple dosage forms. The 
concept of MUDFs was initially introduced in 1950s. 
The production of MUDFs is a common strategy to 
control the release of drug as shown by the 
reproducibility of the release profiles when compared to 
the ones obtained with SUDFs
33
. 
MUDFs have an enough surface area-to-volume ratio 
and provide an ideal shape for the application of film 
coatings. The preparation process necessitates extra care 
and fine adjustments of various equipment’s like 
tableting machines for the preparation of minitablets, 
the volume per dose is usually higher than for tablets 
because of the lower bulk densities of pellets compared 
to compressed tablets, compared to larger single unit 
dosage forms, the specific surface area per dose of 
multiple units is higher and more
34
. These systems 
consist of pellets, granules, beads, microspheres, mini 
or micro tablets filled in to sachets, capsules or 
compressed into tablets. 
Mechanism of drug release from MUDFs: Mainly 
three mechanisms are applied for the drug release 
MUDFs i.e. diffusion, osmosis, erosion. In diffusion it 
occurs through a membrane that controls the movement 
of the drug or solvent between two sides. Both the 
membrane permeability of the drug and the solvent as 
well as the geometry of the device determines the 
diffusion rate of molecules through the membrane. 
Modeling the release characteristics of reservoir devices 
as well as monolithic devices, in which the transport of 
the drug is by a solution diffusion mechanism, involves 
a solution to Flick’s second law for the valid boundary 
conditions
35
. Osmotic pressure is used as the driving 
force for these systems to release the drug in a 
controlled manner. Osmotic pump tablet (OPT) 
generally consists of a core including the drug, an 
osmotic agent, other excipients and semi permeable 
membrane coat
36
. In some cases coatings can be 
designed to wear away gradually with time, thus 
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delivering the drug contained within the particle by 
erosion. 
Various novel drug delivery technologies and dosage 
forms holding promising potential to be effectively 
utilized for the purpose of prolonged release with 
desired pattern and reducing the risk of NSAID induced 
ulceration are given in Table 1. Diagrammatic 
representations of the same are depicted in Fig. 1. 
 
Table 1: Novel technologies/dosage forms that can be explored to overcome NSAIDs induced ulceration in 
arthritic pain management  
Type Characteristics Function Ref 
Tab-in-a-Cap  Multiple release profiles are easily achieved 
by filling immediate release formulation 
(prostaglandin analogue) in outer larger 
capsule and sustained or controlled release 
formulation (NSAID) in inner smaller tablet. 
Provides both controlled and multi-phase 
release for single and combination 
prescription. Patient convenience and 
compliance and cost effective therapy. 
Sustained, pulsed or delayed release profiles 
achievable. 
37 
ACCU- 
BREAK 
 
ACCU-BREAK tablet technology use an 
inactive layer (segment) as the break region.  
The layer containing drug can be scored into 
2, 3 or 4 equal segments, all adjacent to an 
inactive breakable support segment. Thus, a 
tablet could be broken easily into the specific 
dose desired.  
Permits reduction in cost to patients. 
May also promote adherence to therapy by 
reducing the need of frequent administration. 
Dose adjustment as per requirement is 
possible. 
38, 39 
Spheroids/ 
Pallets/ 
Bead 
Controlled-release beads/granules in the 
range from 1 to 2 mm containing drugs may 
be formulated. Each bead begins as an inert 
core onto which the drug is applied. Drug 
release from these beads occurs by a 
diffusion process in a controlled, 
predetermined manner. These dosage form 
enable high drug loading and granules 
produces beads that are of controlled size and 
density with a defined-based granulation 
extrusion and spheronisation techniques.  
Both NSAID and prostaglandin analogue, 
may be simultaneously administered as beads 
in single dosage form with desired release 
profile and drug loading.  
Possibility of aqueous or solvent-based 
granulation. High-speed process is well 
suited for sensitive molecules like proteins 
and enzymes.  
Suitable for high drug loading as required in 
arthritic pain management. 
40, 41 
Multilayer 
dosage forms 
Customizable multilayered oral drug delivery 
platform technology may also be explored. It 
uses well-established ingredients and is 
easily manufactured using conventional 
production equipment. The combination of 
layers, each with different rates of swelling, 
gelling and erosion, controls the drug release 
rate within the body 
Use of highly swellable hydrophilic 
polymers (e.g. HPMC). 
Dynamic control of the surface of the layer 
containing the drug that is exposed to 
surrounding fluids. 
May allow efficient administration of 
NSAID and prostaglandin analogue with 
required release profile and high dose 
delivery in pain management. 
42 
Delayed 
release (Lag) 
based 
technology 
It is used to release the drug from the tablet 
after a pre-determined lag-time that is 
independent of food or pH. It can 
additionally be used for multiple pulse 
delivery of one or more drugs with pre-
determined time intervals between the pulses. 
NSAID and prostaglandin analogue may be 
simultaneously administered on possible 
release pattern to avoid dose dumping and 
associated side effects. 
43 
OROS 
(Osmotic and 
Chronset) 
OROS delivery systems consist of the push-
pull system is comprised of a bilayer or 
trilayer tablet core consisting of one push 
layer and one or more drugs layers. The drug 
layer and the osmotic engine are encased in 
hard capsule which is surrounded by the rate 
controlling semi permeable membrane. A 
barrier layer composed of an inert substance 
separates the drug layer from osmotic engine. 
Using this technology, the drug formulation 
is completely protected from chemical and 
enzymatic degradation in the GIT before 
release, and the timing of release is 
unaffected by GIT contents. 
This technique may be adopted for co-
administration of two drugs for example 
NSAID and prostaglandin analogue.  
A delivery orifice is laser drilled at the 
opposite end of the osmotic engine providing 
an outlet for the drug. 
Contact of NSAID with gastric mucosa may 
be avoided to reduce the possibility of 
ulceration. 
44 
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One Step 
Dry Coating 
Technology 
(OSDrC)
 
 
 
OSDrC technology allows placement of any 
number of cores of any shape into the tablet 
just where they need to be positioned for 
optimum delivery of active pharmaceutical 
ingredients. This technology opens the door 
to new world of pharmaceutical tablet 
manufacturing with advantages like 
uniqueness, high quality, low cost and 
innovativeness. 
This is ideal for manufacturing a variety of 
high-quality drug products at low cost.  
This innovative technology can also replace 
conventional sugar- and film-coated tablets. 
Multiple drugs e.g. NSAID and 
prostaglandin analogue may also be 
administered in different cores. 
45 
Diffucaps/ 
Diffutabs 
In this technology, a unit dosage form, such 
as a capsule for delivering drugs into the 
body in a circadian release fashion, is 
comprised of one or more populations of 
drug-containing particles (beads, pellets, 
granules, etc.). Drug profiles are created by 
layering an active drug onto a neutral core 
such as cellulose spheres and then one or 
more rate-controlling, functional membranes 
are applied. 
Diffutabs are particularly useful for high-
dose products and drugs that require 
sustained release and once-a-day dosing. 
Different formulations containing NSAID 
and prostaglandin analogue may be 
developed and then mixed as a unit dosage 
form for simultaneous administration of 
these drugs with different pattern of release. 
46 
 
 
Figure 1: A: TAB IN CAP; B: ACCU BREAK; C: Spheroids; D: Bead; E: Multilayer dosage forms; F: Delayed 
release (Lag) based technology; G: OROS; H: OSDrC; I: Diffucaps/Diffutabs 
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CONCLUSION AND FUTURE PROSPECTS 
Undoubtedly use of NSAIDs for management of 
arthritic pain is essential to increase the quality of life in 
patients suffering from rheumatic disorders. However 
side effect associated with these drugs are major cause 
of worry for physicians for successive therapeutic 
management of rheumatic inflammation and pain. Multi 
drug based therapy approach especially NSAIDs along 
with prostaglandin analogue is one of the most 
promising approach to overcome ulceration induced by 
high dose and frequency of anti-inflammatory drugs. 
Various novel drug delivery based technologies, as 
discussed in the article, also hold promising potential 
for pain management and patient compliance in these 
ailments without the problem of NSAID-induced 
ulceration. These drug delivery systems may be 
explored in future to find out better strategies for 
effective management of rheumatic disorders.  
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